Business context and reporting period
The supplied filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2020, filed November 12, 2020. This differs from the request metadata naming Cervomed Inc.; verify the intended issuer.
Diffusion is a clinical-stage biopharmaceutical company developing trans sodium crocetinate (TSC), intended to improve oxygen diffusion into hypoxic tissue. It reported no product revenue. Its other candidate, DFN-529, remains in early-stage development.
Financial performance and position
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Revenue | No product revenue | No product revenue | No product revenue | No product revenue |
| Research and development expense | $3.14 million | $1.74 million | $6.85 million | $4.96 million |
| General and administrative expense | $2.11 million | $1.29 million | $4.96 million | $3.56 million |
| Operating loss | $5.27 million | $3.05 million | $11.89 million | $8.59 million |
| Net loss | $4.44 million | $2.80 million | $10.12 million | $8.05 million |
| Net loss attributable to common stockholders | $4.44 million | $2.80 million | $12.07 million | $8.05 million |
| Net cash used in operating activities | Not provided by quarter | $10.16 million | $7.42 million |
The nine-month common-stockholder loss includes a $1.95 million deemed dividend from the May warrant exchange. Profit margins are not meaningful because the company had no product revenue and incurred losses.
At September 30, 2020, cash and cash equivalents were $21.91 million, total current assets $22.68 million, total current liabilities $2.69 million, total liabilities $3.19 million, and stockholders’ equity $28.72 million. The filing reports no credit facilities or committed capital and does not identify outstanding borrowings.
Cash rose $7.73 million during the first nine months: $17.89 million of financing cash inflows, principally from the May 2020 stock offering and warrant exercises, more than offset $10.16 million of operating cash use. No investing cash flows were reported. Common shares outstanding increased to 64.02 million from 33.48 million at year-end 2019; 9.10 million warrants remained outstanding at quarter-end.
Material changes versus the prior comparable period
- Q3 net loss increased by $1.64 million year over year; nine-month net loss increased by $2.08 million.
- Q3 R&D expense rose by $1.39 million, mainly due to COVID-trial manufacturing and clinical costs and expenses associated with winding down the PHAST stroke trial. Nine-month R&D expense rose by $1.88 million, largely reflecting the COVID program ramp-up.
- Q3 G&A expense increased by $0.82 million; the nine-month increase was $1.40 million. The company cited higher professional fees and personnel and stock-compensation costs, including non-recurring costs related to the former CEO’s departure.
- Operating cash use increased by $2.74 million year over year for the nine-month period. Financing inflows increased to $17.89 million from $5.57 million.
Outlook, management commentary, and risks
- Management estimated that quarter-end cash would fund operating expenses and capital requirements into Q4 2022, while also stating that additional funding will be needed to complete TSC development. No additional financing was committed.
- The Phase 1b 100-303 COVID-19 trial was enrolling hospitalized patients; no dose-limiting toxicities had been observed as of the filing. Topline data were expected by the end of Q1 2021. Management was considering adding dose groups, subject to safety review and regulatory approval.
- Management was reviewing TSC development to optimize dose and dosing frequency and to design short-term clinical studies measuring oxygenation. It expected to provide study details by mid-January 2021 and intended to initiate those studies in Q1 2021, funded with cash on hand.
- The company was winding down the PHAST stroke trial and the INTACT glioblastoma trial. Further development in stroke and glioblastoma depended on additional capital or a strategic partnership. The company was also exploring alternatives for DFN-529.
- COVID-19 had disrupted clinical operations, including PHAST enrollment, and could cause further delays or additional costs. The company warned that inability to secure funding could force it to delay, scale back, or stop development or operations, and that financing could dilute shareholders or require relinquishing product rights.
- A former executive’s claim was in arbitration, postponed to summer 2021. The company said it could not estimate any potential loss; an adverse outcome could materially affect its financial position.
- Leadership changed significantly, including appointment of a new CEO and general counsel in September and a new chief medical officer in October. Management reported disclosure controls were effective and no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that Diffusion Pharmaceuticals Inc., rather than Cervomed Inc., is the intended filing issuer.
- Check subsequent cash burn, financing, share issuance, and warrant exercises against the stated runway into Q4 2022.
- Verify the COVID-trial enrollment, safety reviews, any dose expansion, and reported results against the projected Q1 2021 topline timing.
- Review the revised TSC development plans and the status of the PHAST and INTACT wind-downs, partnerships, or funding.
- Monitor the former executive arbitration and any disclosed estimate or resolution of potential exposure.